Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Free Cash Flow (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Free Cash Flow over the past 3 years, most recently at -$42.8 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$42.8 million for Q4 2025, down 192.19% from a year ago — trailing twelve months through Dec 2025 was -$103.2 million (down 69.08% YoY), and the annual figure for FY2025 was -$103.2 million, down 69.08%.
  • Free Cash Flow for Q4 2025 was -$42.8 million at Tonix Pharmaceuticals Holding, down from -$28.5 million in the prior quarter.
  • Over the last five years, Free Cash Flow for TNXP hit a ceiling of -$9.9 million in Q2 2024 and a floor of -$42.8 million in Q4 2025.
  • Median Free Cash Flow over the past 3 years was -$20.8 million (2023), compared with a mean of -$22.8 million.
  • Biggest five-year swings in Free Cash Flow: soared 58.97% in 2024 and later plummeted 192.19% in 2025.
  • Tonix Pharmaceuticals Holding's Free Cash Flow stood at -$22.8 million in 2023, then skyrocketed by 35.76% to -$14.6 million in 2024, then crashed by 192.19% to -$42.8 million in 2025.
  • The last three reported values for Free Cash Flow were -$42.8 million (Q4 2025), -$28.5 million (Q3 2025), and -$15.4 million (Q2 2025) per Business Quant data.